Published :
Tables : 90
Figures : 30
Category : Healthcare
No. of Pages : 180
Report Code : HC-1299
Drug Discovery Services Market Introduction Drug Discovery Services Market is estimated to value over USD 20 billion by 2027 end and register a CAGR of over 11.4% during the forecast period 2020 to 2027. The process of developing a new drug is known as drug discovery. The most widely implemented methods used for discovering drugs are molecular designing, serendipity, drug metabolites, molecular manipulation and random screening. The services associated with drug discovery are particularly designed in order to minimize the timelines and costs of drug discovery. The growing insistence for various cancer treatments, advancements in technology and rising expenditure of healthcare are the crucial factors steering the drug discovery services market growth. As per the WHO, cancer is one of the primary cause of death across the world. The disease has resulted in over 8 million deaths in 2016. The commonly diagnosed cancers are colorectal cancer, stomach cancer, breast cancer, lung cancer and liver cancer. Infections that causes cancer are the ones responsible for over 23% cancer cases in the middle-income and low-income nations. Other factors, for instance, the increasing awareness regarding persistent diseases, growing patient population, incomplete medical requirements, patent of blockbuster drugs getting expired, an inflating framework of the regulations, rising government assistance, and rising funding and reimbursement are continuously contributing to the growth of the drug discovery services market. However, there are some restraints associated with the market. Huge investments with low or no profits margins, stringent regulations by the FDA, and inferior healthcare system in middle and low-income nations may impede the drug discovery services market growth to a significant extent. North America dominates the global market due to the rising presence of persistent diseases and hefty expenditure associated with healthcare. As per the data provided by the centre for disease control and prevention (CDC), over 90 million adults have at least one cardiovascular disease. Furthermore, it is reported that over 16 % of adults in the U.S smoked cigarettes in 2016, which held for more than 490,000 deaths each year. Over 86% of the healthcare cost in the United States i.e. over USD 2.5 trillion is spent for people with mental and chronic health conditions. Key market players involved in the global drug discovery services industry are Thermo Fisher Scientific, Merck, GE Healthcare, Albany Molecular Research, Inc. (AMRI), Charles River Laboratories International, Evotec, Pharmaceutical Product Development, LLC. (Ppd), Jubilant Biosys, Covance, Genscript Biotech Corporation, Aurigene Discovery Technologies, Wuxi Apptec, Syngene Drug Discovery Services Market Segmentation: By Process Target Selection Target Validation Hit-to-Lead Identification Lead Optimization Candidate Validation By Type Medicinal Chemistry Biology Services Drug Metabolism and Pharmacokinetics By Drug Type Small Molecules Biologics By Therapeutic Area Oncology Neurology Cardiovascular Diseases Respiratory Diseases Diabetes Other Therapeutics Areas By Region North America Europe Asia Pacific Rest of the world FutureWise Key Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the drug discovery services market by process, by type, by drug type, by therapeutic area and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific and the rest of the world To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Profiling of companies to evaluate their market shares, strategies, financials and core competencies Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Drug Discovery Services Market is estimated to value over USD 20 billion by 2027 end and register a CAGR of over 11.4% during the forecast period 2020 to 2027.
The process of developing a new drug is known as drug discovery. The most widely implemented methods used for discovering drugs are molecular designing, serendipity, drug metabolites, molecular manipulation and random screening. The services associated with drug discovery are particularly designed in order to minimize the timelines and costs of drug discovery.
The growing insistence for various cancer treatments, advancements in technology and rising expenditure of healthcare are the crucial factors steering the drug discovery services market growth. As per the WHO, cancer is one of the primary cause of death across the world. The disease has resulted in over 8 million deaths in 2016. The commonly diagnosed cancers are colorectal cancer, stomach cancer, breast cancer, lung cancer and liver cancer. Infections that causes cancer are the ones responsible for over 23% cancer cases in the middle-income and low-income nations.
Other factors, for instance, the increasing awareness regarding persistent diseases, growing patient population, incomplete medical requirements, patent of blockbuster drugs getting expired, an inflating framework of the regulations, rising government assistance, and rising funding and reimbursement are continuously contributing to the growth of the drug discovery services market.
However, there are some restraints associated with the market. Huge investments with low or no profits margins, stringent regulations by the FDA, and inferior healthcare system in middle and low-income nations may impede the drug discovery services market growth to a significant extent.
North America dominates the global market due to the rising presence of persistent diseases and hefty expenditure associated with healthcare. As per the data provided by the centre for disease control and prevention (CDC), over 90 million adults have at least one cardiovascular disease. Furthermore, it is reported that over 16 % of adults in the U.S smoked cigarettes in 2016, which held for more than 490,000 deaths each year. Over 86% of the healthcare cost in the United States i.e. over USD 2.5 trillion is spent for people with mental and chronic health conditions.
Key market players involved in the global drug discovery services industry are Thermo Fisher Scientific, Merck, GE Healthcare, Albany Molecular Research, Inc. (AMRI), Charles River Laboratories International, Evotec, Pharmaceutical Product Development, LLC. (Ppd), Jubilant Biosys, Covance, Genscript Biotech Corporation, Aurigene Discovery Technologies, Wuxi Apptec, Syngene
Drug Discovery Services Market Segmentation:
By Process
By Type
By Drug Type
By Therapeutic Area
By Region
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Drug Discovery Services Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Drug Discovery Services Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Drug Discovery Services Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Drug Discovery Services Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Drug Discovery Services Market, By Process Historical Analysis and Forecast 2020-2027 (USD Million) 7.1. Target Selection 7.2. Target Validation 7.3. Hit-to-Lead Identification 7.4. Lead Optimization 7.5. Candidate Validation 8. Global Drug Discovery Services Market, By Type Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Medicinal Chemistry 8.2. Biology Services 8.3. Drug Metabolism and Pharmacokinetics 9. Global Drug Discovery Services Market, By Drug Type Application Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Small Molecules 9.2. Biologics 10. Global Drug Discovery Services Market, By Therapeutic Area Historical Analysis and Forecast 2020-2027 (USD Million) 10.1. Oncology 10.2. Neurology 10.3. Cardiovascular Diseases 10.4. Respiratory Diseases 10.5. Diabetes 10.6. Other Therapeutics Areas 11. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2020-2027 12. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2020-2027 13. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2020-2027 14. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 15.2.1. Saudi Arabia 15.2.2. UAE 15.2.3. South Africa 15.2.4. Egypt 15.3. Market Size (USD Million) Forecast for MEA 2020-2027 16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 16.1. Thermo Fisher Scientific 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. Merck 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. GE Healthcare 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. Albany Molecular Research, Inc. (AMRI) 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5 Charles River Laboratories International 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6 Evotec 16.6.1. Company Overview 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7. Pharmaceutical Product Development, LLC. (Ppd) 16.7.1. Company Overview 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8. Jubilant Biosys 16.8.1. Company Overview 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9. Covance 16.9.1. Company Overview 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10. Genscript Biotech Corporation 16.10.1. Company Overview 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 16.11. Aurigene Discovery Technologies 16.11.1. Company Overview 16.11.2. Product Portfolio 16.11.3. SWOT Analysis 16.11.4. Financial Overview 16.11.5. Strategic Overview 16.12. Wuxi Apptec 16.12.1. Company Overview 16.12.2. Product Portfolio 16.12.3. SWOT Analysis 16.12.4. Financial Overview 16.12.5. Strategic Overview 16.13. Syngene 16.13.1. Company Overview 16.13.2. Product Portfolio 16.13.3. SWOT Analysis 16.13.4. Financial Overview 16.13.5. Strategic Overview 17. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics